CLX vs KMB
Clorox and Kimberly-Clark, both Consumer Defensive
Kimberly-Clark is the larger company at $34B against $12B. On trailing earnings CLX is the cheaper of the two at a P/E of 16.9 against 18.8, a gap that is only a bargain if the two are growing at similar rates. Over the past year CLX returned -13% against -15% for KMB. Ryufin's sector-relative Smart Score puts KMB ahead, 9/10 against 6/10.
| Figure | CLX | KMB |
|---|---|---|
| Last close | $104 | $110 |
| Market cap | $12B | $34B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 16.9 | 18.8 |
| Dividend yield | 4.7% | 4.6% |
| 1-year return | -13% | -15% |
| 5-year return | -32% | -1.6% |
| Ryufin Smart Scoresector-relative, 1–10 | 6/10 | 9/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Clorox
Revenue of $1.7B in Q3 2026, net income $187M. Its largest reported line is Health And Wellness, 38% of the disclosed total.
Kimberly-Clark
Revenue of $4.2B in Q2 2026, net income $345M. Its largest reported line is Babyandchildcareproducts, 41% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.